• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Robustaflavone, a potential non-nucleoside anti-hepatitis B agent.

作者信息

Zembower D E, Lin Y M, Flavin M T, Chen F C, Korba B E

机构信息

MediChem Research, Inc., Lemont, IL 60439, USA.

出版信息

Antiviral Res. 1998 Aug;39(2):81-8. doi: 10.1016/s0166-3542(98)00033-3.

DOI:10.1016/s0166-3542(98)00033-3
PMID:9806485
Abstract

Robustaflavone, a naturally occurring biflavanoid isolated from Rhus succedanea, was found to be a potent inhibitor of hepatitis B virus (HBV) replication in 2.2.15 cells, with an effective concentration (EC50) of 0.25 microM, and a selectivity index (SI, IC50/EC90) of 153. Robustaflavone hexaacetate inhibited HBV replication with an EC50 of 0.73 microM, but exhibited no cytotoxicity at concentrations up to 1000 microM. Combinations of robustaflavone with penciclovir and lamivudine displayed synergistic anti-HBV activity, having the most pronounced effects when the combination ratios were similar to the ratio of EC50 potencies. Thus, a 1:1 combination of robustaflavone and penciclovir exhibited an EC50 of 0.11 microM and an SI of 684, while a 10:1 combination of robustaflavone and lamivudine exhibited an EC50 of 0.054 microM and an SI of 894. Statistical analyses of the combination data using the Combostat program confirmed that robustaflavone exhibited synergism with both penciclovir and lamivudine.

摘要

相似文献

1
Robustaflavone, a potential non-nucleoside anti-hepatitis B agent.
Antiviral Res. 1998 Aug;39(2):81-8. doi: 10.1016/s0166-3542(98)00033-3.
2
Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells.喷昔洛韦是一种在培养的人肝癌细胞中对乙肝病毒复制有选择性抑制作用的药物。
Antimicrob Agents Chemother. 1996 May;40(5):1282-4. doi: 10.1128/AAC.40.5.1282.
3
Antiviral activities of biflavonoids.双黄酮类化合物的抗病毒活性。
Planta Med. 1999 Mar;65(2):120-5. doi: 10.1055/s-1999-13971.
4
Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.用于抗病毒化合物筛选的表达拉米夫定耐药乙型肝炎病毒的稳定细胞系的构建
Antimicrob Agents Chemother. 2003 Jun;47(6):1936-42. doi: 10.1128/AAC.47.6.1936-1942.2003.
5
Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.具有稳定乙型肝炎病毒分泌功能的新型人肝癌细胞系的特性研究,用于评估针对拉米夫定和喷昔洛韦耐药病毒的新化合物。
Antimicrob Agents Chemother. 2000 Dec;44(12):3402-7. doi: 10.1128/AAC.44.12.3402-3407.2000.
6
The S-acyl-2-thioethyl pronucleotide approach applied to acyclovir: part I. Synthesis and in vitro anti-hepatitis B virus activity of bis(S-acyl-2-thioethyl)phosphotriester derivatives of acyclovir.
Antiviral Res. 1999 Jan;40(3):167-78. doi: 10.1016/s0166-3542(98)00059-x.
7
In vitro evaluation of combination therapies against hepatitis B virus replication.针对乙型肝炎病毒复制的联合疗法的体外评估
Antiviral Res. 1996 Jan;29(1):49-51. doi: 10.1016/0166-3542(95)00915-9.
8
Synergistic Interactions between Hepatitis B Virus RNase H Antagonists and Other Inhibitors.乙型肝炎病毒核糖核酸酶H拮抗剂与其他抑制剂之间的协同相互作用
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02441-16. Print 2017 Mar.
9
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.拉米夫定耐药乙型肝炎病毒对阿德福韦和替诺福韦的体外敏感性
Antivir Ther. 2004 Jun;9(3):353-63.
10
Comparison of anti-HBV activity of beta-D- and beta-L-DDA-5'monophosphate prodrugs and effectiveness in combination with lamivudine.β-D-和β-L-DDA-5′单磷酸前药的抗乙肝病毒活性及其与拉米夫定联合使用的效果比较
Nucleosides Nucleotides. 1999 Apr-May;18(4-5):1005-6. doi: 10.1080/15257779908041630.

引用本文的文献

1
Pharmacophore modeling and QSAR analysis of anti-HBV flavonols.抗乙肝病毒黄酮醇的药效团建模与定量构效关系分析
PLoS One. 2025 Jan 13;20(1):e0316765. doi: 10.1371/journal.pone.0316765. eCollection 2025.
2
Metabolites from traditional Chinese botanical drugs with anti-hepatitis B virus activity - a review.具有抗乙型肝炎病毒活性的传统中药植物药代谢产物——综述
Front Pharmacol. 2024 Jul 12;15:1331967. doi: 10.3389/fphar.2024.1331967. eCollection 2024.
3
An overview of anti-Hepatitis B virus flavonoids and their mechanisms of action.
抗乙型肝炎病毒黄酮类化合物概述及其作用机制。
Front Cell Infect Microbiol. 2024 Feb 29;14:1356003. doi: 10.3389/fcimb.2024.1356003. eCollection 2024.
4
An approach to develop potential therapies against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).一种开发针对中东呼吸综合征冠状病毒(MERS-CoV)潜在疗法的方法。
Heliyon. 2024 Feb 9;10(4):e25837. doi: 10.1016/j.heliyon.2024.e25837. eCollection 2024 Feb 29.
5
Novel anti-hepatitis B virus-active catechin and epicatechin from .来自……的新型抗乙型肝炎病毒活性儿茶素和表儿茶素
Exp Ther Med. 2022 Jun;23(6):398. doi: 10.3892/etm.2022.11325. Epub 2022 Apr 15.
6
The anti-hepatitis B virus and anti-hepatotoxic efficacies of solanopubamine, a rare alkaloid from .来自……的一种稀有生物碱茄次碱的抗乙肝病毒和抗肝毒性功效 。 (原文句子不完整,翻译可能存在一定局限性)
Saudi Pharm J. 2022 Apr;30(4):359-368. doi: 10.1016/j.jsps.2022.02.001. Epub 2022 Feb 7.
7
Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches.植物药靶向乙型肝炎病毒 DNA 复制:当前的局限性和未来的方法。
Int J Mol Sci. 2022 Jan 30;23(3):1617. doi: 10.3390/ijms23031617.
8
Exploring the efficacy of naturally occurring biflavone based antioxidants towards the inhibition of the SARS-CoV-2 spike glycoprotein mediated membrane fusion.探索天然二氢黄酮类化合物抗氧化剂抑制 SARS-CoV-2 刺突糖蛋白介导的膜融合的功效。
Virology. 2021 Apr;556:133-139. doi: 10.1016/j.virol.2021.01.015. Epub 2021 Feb 4.
9
Biflavonoids from as probable natural inhibitors against SARS-CoV-2: a molecular docking and molecular dynamics approach.从 中提取的双黄酮类化合物可能是对抗 SARS-CoV-2 的天然抑制剂:一种分子对接和分子动力学方法。
J Biomol Struct Dyn. 2022 Jul;40(10):4376-4388. doi: 10.1080/07391102.2020.1858165. Epub 2020 Dec 10.
10
Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease.针对 SARS-CoV-2 主蛋白酶的天然化合物的分子对接、验证、动力学模拟和药代动力学预测。
J Biomol Struct Dyn. 2022 Feb;40(2):585-611. doi: 10.1080/07391102.2020.1815584. Epub 2020 Sep 8.